Longitudinal associations of lymphocyte subsets with clinical outcomes in chronic fatigue syndrome.
Mehalick, Melissa L, Schmaling, Karen B, Sabath, Daniel E et al. · Fatigue : biomedicine, health & behavior · 2018 · DOI
Quick Summary
This study looked at how different types of immune cells (called lymphocytes) change over 18 months in people with ME/CFS and whether these changes connected to symptom severity and physical ability. Researchers tracked three types of immune cells in 93 ME/CFS patients and measured their fatigue, physical functioning, and energy levels over time. They found that certain immune cell patterns were linked to worse physical function and more symptoms, suggesting the immune system may play a role in ME/CFS severity.
Why It Matters
Understanding which immune cell abnormalities correlate with specific ME/CFS symptoms could help explain disease mechanisms and potentially guide future diagnostic or therapeutic approaches targeting these cell populations. This work contributes to growing evidence that immune dysfunction is not merely incidental to ME/CFS but may actively influence symptom burden and functional impairment over time.
Observed Findings
Higher proportions of naïve T cells were associated with worse physical functioning over 18 months.
Lower proportions of NK cells (CD3-CD16+) were associated with worse physical functioning.
Higher proportions of NK cells (CD3-CD16+) were associated with fewer CFS symptoms.
Lower proportions of naïve T cells were associated with fewer CFS symptoms.
Lymphocyte subset proportions showed modest but measurable relationships to clinical outcomes across multiple timepoints.
Inferred Conclusions
Lymphocyte subset imbalances, particularly involving NK cells and naïve T cells, are modestly related to variations in CFS symptom severity and physical functioning over time.
The pattern of immune dysregulation observed may contribute to differences in disease burden among ME/CFS patients.
Lymphocyte profiling may have potential clinical relevance for understanding individual variation in ME/CFS outcomes.
Remaining Questions
Do these lymphocyte changes reflect cause, effect, or consequence of ME/CFS pathophysiology?
Would interventions that restore lymphocyte proportions to healthy ranges improve clinical outcomes?
What This Study Does Not Prove
This study does not establish that lymphocyte changes cause ME/CFS symptoms—only that they are associated over time. The modest correlations do not prove lymphocytes are the primary driver of fatigue or dysfunction, and correlation does not confirm causation. The small sample size and naturalistic design cannot rule out confounding factors or alternative explanations for the observed associations.